Table 4 Univariate analyses for disease specific-survival and overall survival (n = 57)

Age

  ≤ 67 years

28

1

1

  > 67 years

29

1.05 (0.40–2.73)

1.12 (0.49–2.55)

Sex

 Female

3

1

1

 Male

54

0.29 (0.04–2.25)

0.20 (0.05–0.89)

Subsite

 Glottic

35

1

1

 Supra/sub

22

2.02 (0.78–5.25)

2.31 (1.01–5.28)

Histology

 Well

30

1

1

 Mode/poor

27

0.76 (0.29–2.00)

1.03 (0.45–2.35)

T stage

 T2/T3

26

1

1

 T4

31

8.93 (2.04–39.18)

3.24 (1.27–8.25)

N stage

 N0

37

1

1

 N1–3

20

3.05 (1.17–7.93)

3.58 (1.56–8.19)

M stage

 M0

56

1

1

 M1

1

2.50 (0.33–19.01)

2.04 (0.27–15.32)

Adjuvant therapy

 (−)

19

1

1

 (+)

38

1.83 (0.59–5.61)

1.29 (0.53–3.14)

CD1a⁺ DCs

 Low

43

1

1

 High

14

3.76 (1.31–10.74)

2.45 (1.05–5.70)

S100⁺ DCs

 Low

39

1

1

 High

18

1.49 (0.57–3.92)

1.19 (0.52–2.72)

CD8⁺ CTLs

 Low

33

1

1

 High

24

1.77 (0.65–4.84)

1.33 (0.58–3.06)